BEIJING/SAO PAULO: An experimental coronavirus vaccine developed by China's Sinovac Biotech appeared to be safe in a late-stage clinical trial in Brazil, preliminary results showed on Monday. AstraZeneca PLC and Oxford University are nearing an analysis of their UK coronavirus vaccine trial. Competing candidates developed by AstraZeneca and Johnson & Johnson have had their trials halted in the United States due to safety issues. Brazil is also hosting a Phase 3 trial for AstraZeneca's vaccine candidate, while Johnson & Johnson said last month it aims to expand its final-stage human trials there. CoronaVac uses inactivated vaccine technology, a traditional method that uses killed virus that cannot replicate in human cells to trigger an immune response.

Source: Mint October 20, 2020 03:00 UTC